Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating -0.70% over the last five trades a ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Research analysts at Leerink Partnrs lowered their Q4 2024 earnings per share estimates for Laboratory Co. of Amer ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...